Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the publication of “The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech” in the Aesthetic Surgery Journal.

The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rupture (including a 33-patient MRI cohort), nipple or breast sensitivity loss, incision-related complications, infection, seroma, rippling, hematoma, or BIA-ALCL; the reoperation rate at 3 years was 1%. Patient and surgeon satisfaction was high, with patients reporting an 87% increase in breast satisfaction at 3 years and 90% of surgeons ‘very satisfied’ with their overall experience and none ‘dissatisfied’. Patient follow-up was 93%. The manuscript can be accessed on the Aesthetic Surgery Journal website.

“Breast tissue preservation made possible by our minimally invasive platform is the future of breast augmentation,” said Peter Caldini, Establishment Labs’ Chief Executive Officer. “We expect our minimally invasive platform will generate at least $30 million in revenue in 2026, and it is accelerating TAM expansion on both a dollar and procedure basis. We continue to increase market share in our traditional breast implant business as well as create a new market for women interested in a procedure that offers real differentiation from standard breast augmentation.”

Mia Femtech^® and Preservé^® comprise Establishment Labs’ minimally invasive platform. The breast tissue-preserving procedures can be done without the need for general anesthesia¹ and offer fast recovery*. Mia Femtech utilizes patented tools and technologies, including the Motiva Ergonomix2 Diamond^® implant — the first and only injectable and biocompatible implant² — and delivers natural results with no visible scars on the breast. Preservé uses many of the advances pioneered with Mia, but can be used in a wider cross section of cases and allows for larger sizes.

“This study has tremendous implications for patients and the market. Not only are the outcomes outstanding, but the high follow-up rate gives us the highest confidence in the data,” added Steven Teitelbaum, MD, FACS, Associate Clinical Professor of Plastic Surgery at the UCLA School of Medicine and in private practice in Santa Monica, California. “I have been talking about preserving breast tissue through precise surgery for years, and the Establishment Labs’ method takes that principle to an even higher level, with the lowest-ever complication rate and natural outcomes. Patients are talking about it and are coming into my office specifically asking for it. In 30 years of practice, I’ve never seen this kind of demand for anything. With the smaller incision, reduced anesthesia, faster recovery — and the Motiva implants themselves — this innovation is already interesting a whole new group of patients in breast augmentation.”

Mia Femtech and Ergonomix2 Diamond implants are available in international markets but are not cleared for sale in the United States; Preservé is available in international markets, including in limited release in the United States.

* As compared to traditional breast augmentation.

1. Establishment Labs, CLINR-001035. Fifth progress report for Minimally Invasive Breast Augmentation Traditional Feasibility Study (CLINP-001007). Data on file.

2. Establishment Labs. DDD-006: Device Description Document for MotivaImplants®Ergonomix2®. December 2023. Data on file.

Important Safety Information

The Motiva SmoothSilk^® Round and SmoothSilk Ergonomix^® Silicone Gel Breast Implants are indicated for breast augmentation for women of at least 22 years old. Breast augmentation includes primary breast surgery to increase the breast size, as well as revision surgery to correct or improve the result of an original primary breast augmentation surgery (i.e., revision-augmentation). Breast Implant surgery is contraindicated in women with active infection anywhere in their bodies, with existing cancer or pre-cancer of their breast who have not received sufficient treatment for those conditions, or who are currently pregnant or nursing. Adequate studies have not been performed to confirm the safety of breast implant surgery in women with these conditions or under these circumstances; therefore, if you have any of the conditions or circumstances listed above, breast augmentation surgery with implants should not be performed at this time. Failure to take into consideration these contraindications may increase the risks involved with breast implant surgery and have the potential to cause harm. Patients should be advised that key complications have historically been associated with silicone gel breast surgery and implantation of silicone gel breast implants including, but not limited to, capsular contracture, implant removal, reoperation, infection, and rupture. Further, breast implants are not lifetime devices and patients should visit their healthcare professional, as recommended. For more detailed information about the benefits and risks of Motiva SmoothSilk® Round and SmoothSilk Ergonomix® Silicone Gel Breast Implants, please visit: www.motivausa.com or call Motiva at 1-800-924-5072.

The sale and distribution of this device are restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Motiva USA.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva^® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech^®, a unique minimally invasive experience for breast harmonization, and Preservé^®, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora^® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on February 28, 2025 and in the company's quarterly report on Form 10-Q filed on August 7, 2025, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014998947/en/